Le Lézard
Classified in: Health, Science and technology
Subjects: HEALTH, MISCELLANEOUS, MISCELLANEOUS

Annovis Bio Reports Third Quarter Financial Results and Provides Business Update


MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN ? Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced financial results for the third quarter ended September 30, 2024, and provided a business update.

"The third quarter was marked by important milestones outlining the next steps for buntanetap," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "The FDA gave us the green light to initiate confirmatory Phase 3 studies for early AD, and our team has been working hard to begin them in the coming year. We also strengthened our intellectual property portfolio by filing unique patents protecting new combinations of buntanetap with other medications for improving cognition."

Clinical Updates

Cash Runway and Third Quarter 2024 Financial Results

Conferences

Patents

Team Expansion

About Annovis Bio, Inc. Headquartered in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company's innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contacts
Annovis Bio, Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
[email protected]
Investor Website



These press releases may also interest you

at 08:45
SolarWinds Corporation ("SolarWinds" or the "Company"), a leading provider of simple, powerful, secure observability and IT management software, today announced that it has entered into a definitive agreement to be acquired by Turn/River Capital in...

at 08:45
Accenture has agreed to acquire Staufen AG, a Germany-based management consulting firm, and its subsidiaries1. The acquisition will expand Accenture's capabilities to drive operational excellence and competitiveness in manufacturing and supply...

at 08:43
Country music's rising star, Jovi Greene, is sweeping listeners off their feet with his heartfelt new single, "Lovin' Overdose," dropping just in time for Valentine's Day playlists, available now on Spotify and all major streaming platforms.  ...

at 08:43
After days of intense competition, ACR Poker's flagship Mystery Bounty Venom tournaments awarded more than $10 million in prize money as players from around the world battled for massive bounties and payouts.  The NLH Venom drew 3,519 entrants...

at 08:41
Ten United® Real Estate (United) leaders are featured among 300 distinguished professionals in RISMedia's 2025 Real Estate Newsmakers list. The report shines a spotlight on United's leaders who responded quickly to industry change and seized...

at 08:40
VERSES AI Inc. (CBOE:VERS) ("VERSES" or the "Company"), a cognitive computing company specializing in next-generation intelligent agent systems, announces that on Thursday February 13th the Company will host a webinar discussion of "Intelligence in...



News published on and distributed by: